Charles River Launches Viral Vector Tech Transfer Program to Safeguard Gene Therapy Development
Charles River’s viral vector tech transfer program offers phase-appropriate and customizable frameworks to yield exceptional stability, helping to avoid costly and time-consuming program delays.
- Charles River’s viral vector tech transfer program offers phase-appropriate and customizable frameworks to yield exceptional stability, helping to avoid costly and time-consuming program delays.
- Charles River will showcase its viral vector tech transfer framework at the BIO International Convention , June 3-6, 2024 in San Diego, CA.
- Charles River’s viral vector center of excellence offers viral vector tech transfer and manufacturing to support any stage of the drug development lifecycle, from research-grade viral vector manufacturing for in vitro and in vivo studies to commercial-scale GMP manufacturing.
- Meticulously built to provide a seamless tech transfer at any phase, the viral vector tech transfer program provides stability in times of change.” – Ramin Baghirzade, PhD, Senior Director, Global Head Commercial, Gene Therapy CDMO Services, Charles River